Xilio Therapeutics, Inc. (XLO) Misses Q3 EPS by 6c
Tweet
Share
E-mail
Get Alerts XLO Hot Sheet
Join SI Premium – FREE
Xilio Therapeutics, Inc. (NASDAQ: XLO) reported Q3 EPS of ($0.11), $0.06 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $19.07 million versus the consensus estimate of $16.48 million.
For earnings history and earnings-related data on Xilio Therapeutics, Inc. (XLO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley upgrades CDW on stronger AI-driven server demand
- Over 6 million children enrolled in Trump Accounts program
- Oracle cut 21,000 jobs in past year amid AI shift
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
